NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Axsome Therapeutics, Inc. AXSM
12 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$638.5M
▲ 65.5% vs FY2024
EPS · FY25
$-3.68
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-252.1%
Net margin · FY25
-28.7%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 638.5M
Revenue, FY2025 · full 12-year series below
Revenue
Net income
The company lost 29 cents on every revenue dollar this year.
Per share
USD -3.68
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-252.1%
Return on equity, FY2025
ROE
Operating margin-26.1%
Net margin-28.7%
Return on assets-29.1%
Each USD of equity lost 252 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+133.7%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.05B
Shares outstanding, FY2025
Change, 5 years+36.1%
Change, 10 years+165.7%
The share count grew 36% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 689.8M
total assets, end of FY2025
Total assetsUSD 689.8M
EquityUSD 88.3M
CashUSD 322.9M
Gross debtUSD 187.7M
Net debtUSD -135.2M
Current ratio1.55×
The company holds more cash than debt.
History
12 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Revenue $B
0.6
0.4
0.3
0.1
·
·
·
·
·
·
·
·
Operating income $B
−0.2
−0.3
−0.2
−0.2
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.2
−0.3
−0.2
−0.2
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
·
Income tax $B
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
Net income $B
−0.2
−0.3
−0.2
−0.2
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−3.68
−5.99
−5.27
−4.60
−3.47
−2.77
−2.01
−1.15
−1.27
−1.42
−1.02
−0.66
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−252.1
−231.6
−159.2
−299.0
−201.5
−70.4
−76.1
−350.8
−151.2
−80.0
−56.5
·
Shares out B
0.05
0.05
0.05
0.04
0.04
0.04
0.04
0.03
0.03
0.02
0.02
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
34 of 34
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed